The CurePSP Genetics Program
A legfontosabb adatok
- Hol
- Boston (Egyesült Államok)A helyszín megnézése
Helyszínek itt: Egyesült Államok
- Massachusetts General HospitalBoston, Egyesült ÁllamokContact: Chinyere Obasi, BARésztvevőt keres
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakA vizsgálat adatai
- Ki végzi
- Massachusetts General Hospital
- Azonosító
- NCT06647641
- A regiszteradat frissítve
- 2026. január 14.
- Eredeti leírás
This study is an observational, prospective genetic study. It aims to obtain DNA for research and testing from patients with PSP, CBS, MSA, and related neurological conditions and their families.A teljes eredeti leírásKevesebb
This study is an observational, prospective genetic study. It aims to obtain DNA for research and testing from patients with PSP, CBS, MSA, and related neurological conditions and their families.
Up to 1,000 adults who have been clinically diagnosed with PSP, CBS, MSA, or related neurological conditions will be enrolled. The study intervention involves sequencing of participant blood samples using non-CLIA-approved whole genome sequencing at the National Institutes of Health. Pathogenic variants that are deemed possibly related to these conditions will be confirmed using CLIA-approved testing. The study involves minimal risk to participants.
Bevonási feltételek: Adults (aged 35 or older) with a clinical diagnosis of PSP, CBS, MSA, or a related neurological disease as confirmed by their healthcare provider, or unaffected family members of participants who have reported a family history of relevant neurodegenerative conditions; Meet Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Possible or Probable PSP (32), clinically established or clinically probable MSA (33), Armstrong criteria (2013) for possible or probable CBS (34). Diagnostic certainty will be determined by the treating/referring clinician; Willingness to undergo genetic testing. Participants will have the option to receive relevant genetic test results; Have the capacity to give full informed consent in writing or electronically, or provide consent through a legally authorized representative (LAR)/power of attorney (POA), and have read, understood, and completed the informed consent form; Are able to perform or have a designee who can perform study activities (including completion of either online or orally administered surveys).
Kizáró feltételek: Individuals who have received a blood transfusion within the past 3 months; Individuals who have had a bone marrow transplant within the past 5 years; Individuals who have active hematologic malignancies such as lymphoma or leukemia; Individuals under the age of 35 or age of majority in applicable states at the time of consenting.